These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 773025)

  • 21. Parcopa: a rapidly dissolving formulation of carbidopa/levodopa.
    Med Lett Drugs Ther; 2005 Jan; 47(1201):12. PubMed ID: 15706700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MK 486 and levodopa in treatment of Parkinsonism.
    Lieberman AN; Derby BM; Feigenson J; Goodgold A; Nesbitte J; Resurreccion EC; Valdivia F
    Dis Nerv Syst; 1973; 34(4):167-71. PubMed ID: 4711885
    [No Abstract]   [Full Text] [Related]  

  • 23. [Development of studies on the treatment of Parkinson syndromes using levodopa. I. Short- and medium-term (2 years) effects of the combination levodopa decarboxylase inhibitor].
    Rondot P; Ribadeau Dumas JL; Cardon P
    Therapie; 1975; 30(5):653-66. PubMed ID: 769245
    [No Abstract]   [Full Text] [Related]  

  • 24. [Development of studies on the treatment of parkinsonian syndromes with levodopa. II. Long-term effects of L-DOPA alone or in combination with a decarboxylase inhibitor].
    Rabadeau Dumas JL; Rondot P; Cardon P
    Therapie; 1977; 32(2):161-72. PubMed ID: 898124
    [No Abstract]   [Full Text] [Related]  

  • 25. L-alpha-methyldopa hydrazine (Carbidopa) combined with L-dopa in the treatment of Parkinson's disease.
    Glasgow GL; Henley JW; Willoughby EW
    Aust N Z J Med; 1974 Aug; 4(4):373-8. PubMed ID: 4278910
    [No Abstract]   [Full Text] [Related]  

  • 26. Drug therapy of Parkinsonism dopaminergic drugs.
    Bianchine JR
    Ohio State Med J; 1977 Feb; 73(2):84-5. PubMed ID: 834419
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparison of levodopa with carbidopa or benserazide in parkinsonism.
    Greenacre JK; Coxon A; Petrie A; Reid JL
    Lancet; 1976 Aug; 2(7982):381-4. PubMed ID: 73849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Levodopa and decarboxylase inhibitors in Parkinson's disease].
    Gilland O
    Lakartidningen; 1977 Jan; 74(1-2):37-40. PubMed ID: 318722
    [No Abstract]   [Full Text] [Related]  

  • 29. Treatment of drug-induced psychosis in Parkinson's disease with clozapine.
    Greene P; Cote L; Fahn S
    Adv Neurol; 1993; 60():703-6. PubMed ID: 8420214
    [No Abstract]   [Full Text] [Related]  

  • 30. The long-term effects of combining carbidopa with levodopa for Parkinson's disease.
    Lee MC; Lippert DM; Loewenson RB; Tolosa ES; Resch JA; Martin WE
    Trans Am Neurol Assoc; 1976; 101():262-4. PubMed ID: 829295
    [No Abstract]   [Full Text] [Related]  

  • 31. Effect of a slow release preparation of levodopa on Parkinson's disease in combination with a peripheral decarboxylase inhibitor.
    Saarinen A; Myllylä VV; Tokola O; Hokkanen E
    Acta Neurol Scand; 1978 Dec; 58(6):340-9. PubMed ID: 369277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [CB 154 in the treatment of Parkinson's disease. Results in combination with L-dopa and decarboxylase inhibitor].
    Meco G; Casacchia M; Zamponi A; Agnoli A
    Acta Neurol (Napoli); 1976; 31(4):479-48. PubMed ID: 1037427
    [No Abstract]   [Full Text] [Related]  

  • 33. [Clinical significance of cramps of the lower extremities in patients with parkinsonism].
    Yu HZ
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):217-8. PubMed ID: 4075911
    [No Abstract]   [Full Text] [Related]  

  • 34. [Effects and side effects to levodopa in parkinsonism- results of a collaborative study. (5) Combined therapy with a peripheral decarboxylase inhibitor].
    Omoto T
    Rinsho Shinkeigaku; 1976 Dec; 16(12):879-80. PubMed ID: 1035531
    [No Abstract]   [Full Text] [Related]  

  • 35. Combined use of benserazide and carbidopa in Parkinson's disease.
    Lieberman AN; Goldstein M; Gopinathan G; Neophytides A; Hiesiger E; Walker R; Nelson J
    Neurology; 1984 Feb; 34(2):227-9. PubMed ID: 6538015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment of patients with vascular parkinsonism with the preparations nakom and madopar].
    Kamenetskiĭ VK
    Klin Med (Mosk); 1984 Apr; 62(4):112-6. PubMed ID: 6737958
    [No Abstract]   [Full Text] [Related]  

  • 37. [Decarboxylase inhibitors combined with L-dopa in the treatment of Parkinson's disease].
    Rondot P
    Rev Prat; 1974 Mar; 24(15):1211-2, 1215-6, 1219. PubMed ID: 4416964
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment of parkinsonism with N-n-propyl norapomorphine and levodopa (with or without carbidopa).
    Papavasiliou PS; Cotzias GC; Rosal VL; Miller ST
    Arch Neurol; 1978 Dec; 35(12):787-91. PubMed ID: 363104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Comparison between results achieved by administering L-dopa and Sinemet in parkinsonism in the light of our records].
    Szulc-Kuberska J; Niewodniczy A; Poźniak-Patewics E; Wolczyk-Orzechowska M
    Neurol Neurochir Pol; 1975; 9(5):611-5. PubMed ID: 1186952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Levodopa-associated hemifacial dystonia.
    Mark MH; Sage JI
    Mov Disord; 1991; 6(4):383. PubMed ID: 1758464
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.